Drew Ranieri
Stock Analyst at Morgan Stanley
(1.18)
# 3,352
Out of 4,814 analysts
164
Total ratings
40.45%
Success rate
-13.89%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $4.25 | +41.18% | 4 | Mar 5, 2025 | |
| GMED Globus Medical | Upgrades: Overweight | $83 → $100 | $71.20 | +40.45% | 12 | Dec 2, 2024 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $346.67 | +28.36% | 9 | Dec 2, 2024 | |
| SIBN SI-BONE | Maintains: Overweight | $21 → $19 | $13.35 | +42.32% | 15 | Aug 6, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $15.79 | +71.05% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $6.46 | +23.84% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $22.01 | -0.05% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $10.43 | -23.30% | 13 | Jul 15, 2024 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $19 → $16 | $10.24 | +56.33% | 8 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $10.84 | +661.07% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $15.02 | +153.00% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $56.80 | +69.01% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $12.09 | +115.05% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $200.40 | +47.21% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $128.26 | +118.31% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $7.76 | -35.53% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $27.87 | +151.21% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $481.34 | -37.67% | 6 | Apr 25, 2022 |
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $4.25
Upside: +41.18%
Globus Medical
Dec 2, 2024
Upgrades: Overweight
Price Target: $83 → $100
Current: $71.20
Upside: +40.45%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $346.67
Upside: +28.36%
SI-BONE
Aug 6, 2024
Maintains: Overweight
Price Target: $21 → $19
Current: $13.35
Upside: +42.32%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $15.79
Upside: +71.05%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $6.46
Upside: +23.84%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $22.01
Upside: -0.05%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $10.43
Upside: -23.30%
Alphatec Holdings
Jul 15, 2024
Maintains: Overweight
Price Target: $19 → $16
Current: $10.24
Upside: +56.33%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $10.84
Upside: +661.07%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $15.02
Upside: +153.00%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $56.80
Upside: +69.01%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $12.09
Upside: +115.05%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $200.40
Upside: +47.21%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $128.26
Upside: +118.31%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $7.76
Upside: -35.53%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $27.87
Upside: +151.21%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $481.34
Upside: -37.67%